BRIEF published on 04/24/2026 at 07:05, 6 months 12 days ago BB Biotech AG Reports Q1 2026 Interim Results Drug Development Net Loss Investment Portfolio BB Biotech Q1 2026
BRIEF published on 04/24/2026 at 07:05, 6 months 12 days ago BB Biotech Q1 2026 Achievements and Strategic Shifts Net Asset Value Portfolio Repositioning New Investments BB Biotech Performance Dividend Inclusion
PRESS RELEASE published on 04/24/2026 at 07:00, 6 months 12 days ago EQS-Adhoc: BB Biotech AG publishes its interim report BB Biotech AG publishes its interim report for the first quarter of 2026, showing a net loss of CHF 21 mn compared to CHF 241 mn in the same period of 2025 Investment Company BB Biotech AG Interim Report Results Loss
PRESS RELEASE published on 04/24/2026 at 07:00, 6 months 12 days ago BB Biotech Q1 2026: Share price outperformance, narrowing discount and active portfolio repositioning BB Biotech AG reports Q1 2026 results with share price outperformance, narrowing discount, and active portfolio repositioning. Eleven new investments made in biotech sector Share Price BB Biotech AG Investments Portfolio Repositioning Q1 2026
BRIEF published on 03/19/2026 at 17:45, 7 months 18 days ago BB Biotech AG's AGM Approves Proposals and Dividend Annual General Meeting Investment Strategy Board Re-election Dividend Approval BB Biotech
PRESS RELEASE published on 03/19/2026 at 17:40, 7 months 18 days ago Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.25 per share Shareholders at BB Biotech AG's AGM approve CHF 2.25 dividend per share. Board proposals endorsed. Re-election of board members Shareholders Dividend AGM BB Biotech AG Board Proposals
BRIEF published on 02/20/2026 at 07:05, 8 months 14 days ago BB Biotech AG Releases 2025 Annual Report Dividend Proposal Biotechnology Sector Net Profit Increase BB Biotech 2025 Annual Report
BRIEF published on 02/20/2026 at 07:05, 8 months 14 days ago BB Biotech's 2025 Annual Report Highlights Strong Financial Gains Annual Report Portfolio Value Shareholder Returns BB Biotech Financial Gains
PRESS RELEASE published on 02/20/2026 at 07:00, 8 months 14 days ago EQS-Adhoc: BB Biotech AG publishes its 2025 annual report BB Biotech AG releases its 2025 annual report, reporting a strong performance with a +34.2% total return in CHF. The annual report includes detailed information on the biotechnology sector and the company's investments Financial Results Investment BB Biotech AG Biotechnology Sector 2025 Annual Report
PRESS RELEASE published on 02/20/2026 at 07:00, 8 months 14 days ago Annual Report 2025: BB Biotech delivers strong performance and portfolio value realization BB Biotech AG's Annual Report 2025 showcases strong performance and portfolio value realization. Shareholder returns, active capital management, and refined investment processes highlighted BB Biotech AG Portfolio Value Shareholder Returns Annual Report 2025 Investment Processes
Published on 11/06/2026 at 13:00, 5 hours 34 minutes ago Alaska Energy Metals Achieves High Extraction Rates of Metals from Hydromet Testing, Nikolai Nickel Project, Alaska
Published on 11/06/2026 at 12:30, 6 hours 4 minutes ago Relevant Gold Receives Expanded Drilling Approvals for the Lewiston Project in Wyoming
Published on 11/06/2026 at 12:30, 6 hours 4 minutes ago Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights
Published on 11/06/2026 at 05:15, 13 hours 19 minutes ago Valeo and QNX Unveil A New Smart Camera Platform at CIIE, Secures Multiple Design Wins
Published on 11/06/2026 at 17:41, 53 minutes ago Turkiye Garanti Bankasi A.S.: Daily Share Buyback Transactions
Published on 11/06/2026 at 14:50, 3 hours 44 minutes ago New UN guide keeps people in charge of AI in smart cities
Published on 11/06/2026 at 17:54, 40 minutes ago Disclosure of Share Capital and Voting Rights as of October 31, 2026
Published on 11/06/2026 at 17:35, 59 minutes ago Disclosure of the number of shares and the total number of voting rights as of October 31, 2026
